Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 939

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 6
Chunk 939
---
 of
issuance and a reduction of the exercise price of the Existing Warrants to $0.3736 per share, representing the closing price on
March 14, 2025, but only with respect to a cash exercise under the Existing Warrants (as reduced from the current respective
exercise price per share as set forth in the Existing Warrants).

The
closing took place on March 17, 2025. Gross proceeds to the Company from the exercise of the Existing Warrants was  $2,316,320,
prior to deducting closing costs and placement agent fees as further described below. The Company intends to use the net proceeds from
the offering for working capital and general corporate purposes.

As
a result of the Holder exercising the Existing Warrants, the Company issued an aggregate of 775,000 shares of its common stock. The shares
underlying the Existing Warrants have all been registered on Form S-1 registration statement (Registration Number 333-278188).

The
Company agreed to file a resale registration statement registering the shares underlying the Replacement Warrants (“Resale Registration
Statement”) within ninety (90) days of the date of the Agreement and to use commercially reasonable best efforts to cause the Resale
Registration Statement to be effective on or prior to the 150th calendar day after the date of the Agreement.

 54 

Subject to the terms
of the Agreement, the Company will be required to pay certain liquidated damages if the shares underlying the New Warrants are not filed
within the ninety (90) period, as more fully described in the Agreement.

The
Company further agreed that until sixty (60) days after the closing date of the warrant exercise, it will not (other than in connection
with limited enumerated exceptions) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares
of common stock or common stock equivalents or file any registration statement or any amendment or supplement (other than the registration
statement registering the shares underlying the Replacement Warrants).

In
connection with the transactions contemplated in the Agreement, the Company agreed to pay its placement agent, Maxim Group, LLC (the “Agent”)
the following compensation, (i) a cash fee equal to 6.0% of the gross proceeds received by the Company in the transactions contemplated
by the Agreement, and (ii) legal fees and out-of-pocket expenses of $15,000.

On May 17, 2024, we
closed a public